Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Auxano Advisors LLC

Auxano Advisors LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 29.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,392 shares of the company's stock after purchasing an additional 8,949 shares during the quarter. Novo Nordisk A/S accounts for approximately 0.7% of Auxano Advisors LLC's holdings, making the stock its 24th biggest holding. Auxano Advisors LLC's holdings in Novo Nordisk A/S were worth $2,735,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL raised its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $29,000. Transce3nd LLC purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $27,000. Finally, Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $0.97 during midday trading on Friday, hitting $64.32. The company had a trading volume of 8,032,293 shares, compared to its average volume of 7,363,987. The business has a 50-day simple moving average of $70.34 and a two-hundred day simple moving average of $74.38. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $139.74. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $287.19 billion, a price-to-earnings ratio of 19.03, a price-to-earnings-growth ratio of 1.26 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion during the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NVO. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.